Keapstone Therapeutics receives additional funding to expand programme
Parkinson’s UK is pleased to announce that it has agreed to provide up to £320,000 additional funding to Keapstone Therapeutics to expand its current research programme to develop molecules with the potential to create drugs that can slow or stop the progression of Parkinson’s.
Keapstone Therapeutics was launched in March 2017 by Parkinson’s UK and the University of Sheffield. It is part of Parkinson’s UK’s new Virtual Biotech venture and combines world-leading research from the University with funding and expertise from the charity to help develop revolutionary new drugs
Dr Jan Kulagowski, Drug Discovery Manager at Parkinson’s UK, comments:
“We’re pleased to announce this additional funding support for Keapstone Therapeutics which demonstrates our continued commitment to this promising programme which holds real potential for delivering potential new treatments for Parkinson’s.”